EE9900535A - Fumaarhappe derivaatide kasutamine - Google Patents

Fumaarhappe derivaatide kasutamine

Info

Publication number
EE9900535A
EE9900535A EEP199900535A EEP9900535A EE9900535A EE 9900535 A EE9900535 A EE 9900535A EE P199900535 A EEP199900535 A EE P199900535A EE P9900535 A EEP9900535 A EE P9900535A EE 9900535 A EE9900535 A EE 9900535A
Authority
EE
Estonia
Prior art keywords
fumaric acid
acid derivatives
administration
salts
alone
Prior art date
Application number
EEP199900535A
Other languages
English (en)
Inventor
K. Joshi Rajendra
Strebel Hans-Peter
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of EE9900535A publication Critical patent/EE9900535A/et
Publication of EE03999B1 publication Critical patent/EE03999B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP199900535A 1997-05-20 1998-04-01 Fumaarhappe derivaatide kasutamine EE03999B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19721099A DE19721099C2 (de) 1997-05-20 1997-05-20 Verwendung von Fumarsäurederivaten
PCT/EP1998/001894 WO1998052549A2 (de) 1997-05-20 1998-04-01 Verwendung von fumarsäurederivaten

Publications (2)

Publication Number Publication Date
EE9900535A true EE9900535A (et) 2000-06-15
EE03999B1 EE03999B1 (et) 2003-04-15

Family

ID=7829995

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900535A EE03999B1 (et) 1997-05-20 1998-04-01 Fumaarhappe derivaatide kasutamine

Country Status (25)

Country Link
US (1) US6436992B1 (et)
EP (1) EP0980242B1 (et)
JP (1) JP3881038B2 (et)
CN (1) CN1153569C (et)
AT (1) ATE232093T1 (et)
AU (1) AU730441B2 (et)
BG (1) BG64613B1 (et)
BR (1) BR9809655A (et)
CA (1) CA2248955C (et)
CZ (1) CZ299960B6 (et)
DE (2) DE19721099C2 (et)
DK (1) DK0980242T3 (et)
EE (1) EE03999B1 (et)
ES (1) ES2190588T3 (et)
HK (1) HK1027512A1 (et)
HU (1) HU227697B1 (et)
IL (1) IL132819A (et)
NO (1) NO326815B1 (et)
NZ (1) NZ501755A (et)
PL (1) PL190864B1 (et)
RS (1) RS49654B (et)
RU (1) RU2197963C2 (et)
SK (1) SK285897B6 (et)
TR (1) TR199902587T2 (et)
WO (1) WO1998052549A2 (et)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
EP1372634B1 (de) 2001-01-12 2009-11-11 Biogen Idec International GmbH Verwendung von fumarsäureamiden
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
EP1663197B1 (en) 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
PL2801354T3 (pl) * 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2007148744A1 (ja) * 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
EP3295936A1 (en) 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
HUE025878T2 (en) * 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
US20140163100A1 (en) * 2011-05-26 2014-06-12 Biogen Idec Ma Inc. Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
US9422226B2 (en) 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
TWI486339B (zh) 2012-02-07 2015-06-01 Xenoport Inc □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法
EP2811994A4 (en) 2012-02-07 2016-01-13 Biogen Ma Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN104415026A (zh) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 氘代富马酸衍生物在治疗多发性硬化症中的应用
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
US20180021286A1 (en) * 2015-02-02 2018-01-25 Enspire Group LLC Stabilized dialkyl fumarate compositions
CA2972179C (en) 2015-02-08 2021-10-26 Alkermes Pharma Ireland Limited Monomethylfumarate prodrug compositions
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
ES2826825T3 (es) 2015-03-27 2021-05-19 Symbionyx Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la psoriasis
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
AU2017216861A1 (en) * 2016-02-12 2018-10-04 Universität Zürich Dimethyl fumarate (DMF) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
CN107973714A (zh) * 2017-12-26 2018-05-01 荆门医药工业技术研究院 一种富马酸单乙酯盐类的制备方法
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
WO2022132978A1 (en) * 2020-12-18 2022-06-23 Upsher-Smith Laboratories, Llc Modified release solid oral dosage form for once daily administration of monomethyl fumarate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US4346118A (en) * 1980-05-02 1982-08-24 University Of Delaware Antimicrobial agents added to animal feeds
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
DE3531597A1 (de) * 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4768439A (en) * 1987-10-23 1988-09-06 Singer Stewart M Flare composition and flare comprising said composition
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH06345644A (ja) * 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
JPH07278187A (ja) * 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) * 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) * 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물

Also Published As

Publication number Publication date
NO326815B1 (no) 2009-02-23
DE59807122D1 (de) 2003-03-13
AU730441B2 (en) 2001-03-08
ATE232093T1 (de) 2003-02-15
SK41599A3 (en) 2000-12-11
WO1998052549B1 (de) 1999-05-14
PL335381A1 (en) 2000-04-25
PL190864B1 (pl) 2006-02-28
HU227697B1 (en) 2011-12-28
TR199902587T2 (xx) 2000-08-21
WO1998052549A3 (de) 1999-04-08
US6436992B1 (en) 2002-08-20
SK285897B6 (sk) 2007-10-04
JP2000513023A (ja) 2000-10-03
NO991342D0 (no) 1999-03-19
HUP0001684A3 (en) 2001-09-28
CA2248955C (en) 2001-08-14
IL132819A (en) 2004-12-15
IL132819A0 (en) 2001-03-19
AU7213698A (en) 1998-12-11
CA2248955A1 (en) 1997-05-20
CZ299960B6 (cs) 2009-01-07
EE03999B1 (et) 2003-04-15
DE19721099A1 (de) 1998-11-26
CN1257426A (zh) 2000-06-21
BR9809655A (pt) 2000-07-11
CZ108099A3 (cs) 1999-08-11
BG103335A (en) 2000-04-28
WO1998052549A2 (de) 1998-11-26
YU57599A (sh) 2001-12-26
DE19721099C2 (de) 1999-12-02
EP0980242A2 (de) 2000-02-23
DK0980242T3 (da) 2003-04-14
EP0980242B1 (de) 2003-02-05
JP3881038B2 (ja) 2007-02-14
BG64613B1 (bg) 2005-09-30
RU2197963C2 (ru) 2003-02-10
RS49654B (sr) 2007-09-21
CN1153569C (zh) 2004-06-16
NO991342L (no) 1999-11-16
HUP0001684A2 (hu) 2000-09-28
ES2190588T3 (es) 2003-08-01
HK1027512A1 (en) 2001-01-19
NZ501755A (en) 2001-07-27

Similar Documents

Publication Publication Date Title
EE9900535A (et) Fumaarhappe derivaatide kasutamine
ATE221379T1 (de) Verfahren zur behandlung infektiöser respiratorischer erkrankungen
DE69805846T2 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
HUP9701540A1 (hu) A gasztrointesztinális keringést elősegítő gyógyászati készítmény
DE69317433T2 (de) Ungesättigte aliphatische dicarbonsäuren
HK1161115A1 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
AR008371A1 (es) Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
NO179245C (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
NO923393L (no) Fremgangsmaate for inhibering av korrosjon i broenner som syrebehandle
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
DK0657431T3 (da) 4-Phenyl-3-substituerede 1,4-dihydropyridinestere med cerebral virkning.
DE69630876D1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
ES2126643T3 (es) Sales de un acido quinoloncarboxilico.
DK0868181T3 (da) Anvendelse af alfa,alfa-diphenyleddikesyre-4-(N-methyl-piperidyl)-estere som spasmoanalgetikum

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
HD1A Correction of address